Dolutegravir Pill

DRUG2 trials

Sponsors

University of North Carolina, Chapel Hill, University of Nairobi

Conditions

HIV-1-infectionHIV/AIDS

Phase 3

Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance

RecruitingNCT06747507

University of NairobiHIV-1-infection

Start: 2025-09-01End: 2027-07-31Target: 392Updated: 2025-09-11

Phase 4

ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence

CompletedNCT03218592

University of North Carolina, Chapel HillHIV/AIDS

Start: 2017-06-28End: 2018-12-07Updated: 2019-11-22

Related Papers

The dolutegravir failure cohort: A multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocol

PLoS ONE2026-03-13

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Nonadherence: Protocol for a Single-Arm Cross-sectional Study

JMIR Research Protocols2023-03-021 citations

A Novel Algorithm to Improve PrEP Adherence Monitoring Using Dried Blood Spots

Clinical Pharmacology & Therapeutics2023-01-0913 citations